Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.
The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.
Management for specific patient populations, along with links to other COVID-19 related guidelines, are provided separately. (See "Society guideline links: COVID-19 – Index of guideline topics", section on 'Society guideline topics by medical specialty'.)
International
●World Health Organization (WHO): Therapeutics and COVID-19 – Living guideline (2022)
●WHO: Living guidance for clinical management of COVID-19 (2021)
●Endocrine Society (ES): A statement on dexamethasone and COVID-19 (2020)
●WHO: Corticosteroids for COVID-19 – Living guidance (2020)
●WHO: Use of chest imaging in COVID-19 – A rapid advice guide (2020)
Canada
●PHAC: COVID-19 signs, symptoms and severity of disease – A clinician guide (2022)
●PHAC: National case definition – Coronavirus disease (COVID-19) (2022)
●Canadian Paediatric Society (CPS): Position statement on the acute management of COVID-19 in paediatrics (2020, updated 2021)
●Multicenter interim guidance on use of antivirals for children with COVID-19/SARS-CoV-2 (2020)
United States
●Centers for Disease Control and Prevention (CDC): Clinical care quick reference for COVID-19 (2022)
●Infectious Diseases Society of America (IDSA): Guidelines on the treatment and management of patients with COVID-19 (2020, updated 2022)
●National Institutes of Health (NIH): COVID-19 treatment guidelines (2022)
•Anti-SARS-CoV-2 antibody products
•Cell-based therapy under evaluation for the treatment of COVID-19
•Clinical management of adults
•Clinical management of children
•Clinical spectrum of SARS-CoV-2 infection
•Considerations for certain concomitant medications in patients with COVID-19
●CDC: Interim guidance on evaluating and caring for patients with post-COVID conditions (2021)
●Multicenter interim guidance on use of antivirals for children with COVID-19/SARS-CoV-2 (2020)
Europe
●European Respiratory Society (ERS): Statement on long COVID-19 follow-up (2022)
●American Thoracic Society (ATS)/ERS: Updated guidance on the management of COVID-19 (2020)
United Kingdom
●National Health Service (NHS) England: Acute use of non-steroidal anti-inflammatory drugs (NSAIDs) in people with or at risk of COVID-19 – Guidance (2020, updated 2022)
●NHS England: COVID-19 therapy – Corticosteroids including dexamethasone and hydrocortisone (2020, updated 2022)
●NHS England: Interim clinical commissioning policy – Neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 (2021, updated 2022)
●National Institute for Health and Care Excellence (NICE): COVID-19 rapid guideline – Managing COVID-19 (2021, updated 2022)
●UK Health Security Agency (UKHSA): Guidance on COVID-19 – Investigation and initial clinical management of possible cases (2020, updated 2022)
●NICE: COVID-19 rapid guideline – Managing the long-term effects of COVID-19 (2020, updated 2021)
●UKHSA: Guidance on COVID-19 – Investigation and management of suspected SARS-CoV-2 reinfections (2021)
●UKHSA: Guidance on COVID-19 – Long-term health effects (2020, updated 2021)
●Scottish Intercollegiate Guidelines Network (SIGN): Guideline on managing the long-term effects of COVID-19 (2020, updated 2021)
India
●MHFW: Revised discharge policy for COVID-19 (2022)
●MHFW: Clinical management protocol for COVID-19 (in adults) (2021)
●MHFW: National comprehensive guidelines for management of post-COVID sequelae (2021)
●MHFW: Post COVID management protocol (2020)
Australia–New Zealand
●National COVID-19 Clinical Evidence Taskforce: Living guidelines on caring for people with COVID-19 (2022)
●NSW Health: Interim guidance on use of antiviral and immunomodulation therapy in COVID-19 (2022)
●NSW Health: Care of adult patients with COVID-19 in acute inpatient wards (2021)
Japan
●[In Japanese] Choosing Wisely Japan: Do not prescribe unproven therapeutic agents to COVID-19 patients except in approved clinical trials (2020)
●[In Japanese] National Institute of Infectious Diseases (NIID): New coronavirus infectious disease, health and infection control at home treatment (2020)
Resources for patients — The following links provide resources about COVID-19 for non-clinicians. These resources come from select society and government-sponsored guidelines from several countries and regions around the world.
●[International] World Health Organization (WHO): Coronavirus disease (COVID-19) – Home care for families and caregivers
●[United States] Centers for Disease Control and Prevention (CDC): If you are sick or caring for someone
●[United Kingdom] National Health Service (NHS): How to look after yourself at home if you have coronavirus (COVID-19) or symptoms of COVID-19
●[United Kingdom] NHS: Long-term effects of coronavirus (long COVID)
UpToDate also offers "The Basics" patient education pieces, which are written by the doctors and editors at UpToDate. These are written in plain language, at the 5th to 6th grade reading level, and answer the main questions a person is likely to have. (See "Patient education: COVID-19 overview (The Basics)" and "Patient education: COVID-19 and children (The Basics)" and "Patient education: COVID-19 and pregnancy (The Basics)" and "Patient education: COVID-19 vaccines (The Basics)".)
